Results 331 to 340 of about 349,757 (388)

Supplementary Table 3 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500

Vicky A. Appleman, Atsushi Matsuda, Michelle L. Ganno, Dong Mei Zhang, Emily Rosentrater, Angel E. Maldonado Lopez, Angelo Porciuncula, Tiquella Hatten, Camilla L. Christensen, Samantha A. Merrigan, Hong Myung Lee, Min Young Lee, Charlotte I. Wang, Linlin Dong, Jian Huang, Natasha Iartchouk, Jianing Wang, He Xu, Tomoki Yoneyama, Konstantin I. Piatkov, Satyajeet Haridas, Carole E. Harbison, Richard C. Gregory, Alexander Parent, Neil Lineberry, Chris Arendt, Kurt A. Schalper, Adnan O. Abu‐Yousif   +27 more
openalex   +1 more source

Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC. [PDF]

Front Oncol
Ramlau R, Kowalski DM, Szczęsna A, Szczylik C, Ou Y, Köbel M, Siegers GM, Gaspar KJ, Lee B, Roszkowski-Sliz K.   +9 more
europepmc   +1 more source

Supplementary Figure 12 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500

Vicky A. Appleman, Atsushi Matsuda, Michelle L. Ganno, Dong Mei Zhang, Emily Rosentrater, Angel E. Maldonado Lopez, Angelo Porciuncula, Tiquella Hatten, Camilla L. Christensen, Samantha A. Merrigan, Hong Myung Lee, Min Young Lee, Charlotte I. Wang, Linlin Dong, Jian Huang, Natasha Iartchouk, Jianing Wang, He Xu, Tomoki Yoneyama, Konstantin I. Piatkov, Satyajeet Haridas, Carole E. Harbison, Richard C. Gregory, Alexander Parent, Neil Lineberry, Chris Arendt, Kurt A. Schalper, Adnan O. Abu‐Yousif   +27 more
openalex   +1 more source

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. [PDF]

Cell Rep Med
High PC, Liang Z, Guernsey-Biddle C, Subramanian S, Shyu YM, Aldana AM, Toh Y, Carmon KS.   +7 more
europepmc   +1 more source

Supplementary Figure 5 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500

Vicky A. Appleman, Atsushi Matsuda, Michelle L. Ganno, Dong Mei Zhang, Emily Rosentrater, Angel E. Maldonado Lopez, Angelo Porciuncula, Tiquella Hatten, Camilla L. Christensen, Samantha A. Merrigan, Hong Myung Lee, Min Young Lee, Charlotte I. Wang, Linlin Dong, Jian Huang, Natasha Iartchouk, Jianing Wang, He Xu, Tomoki Yoneyama, Konstantin I. Piatkov, Satyajeet Haridas, Carole E. Harbison, Richard C. Gregory, Alexander Parent, Neil Lineberry, Chris Arendt, Kurt A. Schalper, Adnan O. Abu‐Yousif   +27 more
openalex   +1 more source

An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia. [PDF]

Blood Neoplasia
Gordon PM, Williams RL, Ostergaard J, Lee KC, Bui HN, Muretta JM, Wilson BS, Beder T, Baldus CD, Lambert L, Deonovic BE, Singleton T, Tasian SK, Winter SS.   +13 more
europepmc   +1 more source

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy. [PDF]

World J Urol
Kessler C, von Brandenstein M, Klümper N, Krausewitz P, Storz E, Rieger C, Sperber L, Paffenholz P, Tolkach Y, Wirtz R, Eckstein M, Heidenreich A, Weiten R.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs.

Journal of Natural Products, 2022
Dolastatin 10 is an extremely potent broad-spectrum antitubulin anticancer pentapeptide isolated from Dolabella auricularia. The two-dimensional structure was elucidated by NMR and mass spectrometric analyses. The absolute configuration was determined by
Sheo B. Singh
semanticscholar   +1 more source